Bowen Acquisition Corp
Status: Live Deal
U=S+R
R=S/10
IPO Proceeds, $M | $69.00M |
---|---|
IPO Date | Jul 12, 2023 |
CEO | Jiangang Luo |
Left Lead | EarlyBirdCapital |
IPO Cash in Trust | 101.0% |
SPAC Tenor | 15 + 3 |
IPO Sector |
General
Businesses in Asia |
IPO Geography | Asia |
Target Company | Qianzhi BioTech |
Deal Announced | Jan 18, 2024 |
Deal Size, $M | TBD |
Deal Sector | Healthcare |
Deal Geography | Asia |
SEC Filings | www.sec.gov |
Approval Vote | Jan 13, 2025 |
Amendment Vote | Jan 7, 2025 |
BOWN
BOWNU
BOWNR
Price | $10.93 |
---|---|
Last closing price | $10.95 |
H/L, 52-week | $10.10 / $10.31 |
Volume, today | 1,379 |
Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Bowen Acquisition Corp:
- Structure and cap table
- 6 directors & officers
- 17 filings and events
- 2 underwriters
- 5 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
Name | Age | Title |
---|---|---|
Na Gai | 36 | Chairwoman |
Jiangang Luo | 54 | CEO |
Jing Lu | 58 | CFO |
Lawrence Leighton | 88 | Director |
Wei Li | 44 | Director |
Jun Zhang | 59 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
EarlyBirdCapital | BR | 5,100,000 | units |
Revere Securities | 900,000 | ||
6,000,000 | units | ||
Up-Front UW fee | 2.50 | % | |
BCMA | 3.50 | % |
Sign in to view more advisor data.